Windlas Biotech Limited
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
What Windlas files
- Investor Meet58
- Others37
- Updates17
- Board Meeting10
- PPTs8
- Important6
Windlas Biotech's committee approved granting 37,000 employee stock options/units under ESOS 2023 and Windlas Plan 2025. Each unit converts to one Rs 5 face value equity share. This move aims to align employee interests, with vesting periods ranging 1-4 years. Potential for future equity dilution.
Windlas Biotech's Codeine cough syrup production is temporarily suspended after a Show Cause Notice from drug authorities. This product line contributed Rs. 55.21 Cr to current FY revenue. Only Codeine-based syrups are affected; other production continues normally.
Windlas Biotech Limited has announced a board meeting to discuss the financial results for the quarter and half-year. The company has completed dispatch of its 24th Annual General Meeting notice and Annual Report for FY 2024-25 to shareholders. No material operational changes, business developments, new orders, or fines were reported....
Windlas Biotech Limited has announced a board meeting to review the financial results for the quarter and half-year. The company reports strong operational progress with enhanced manufacturing capabilities and expanded contract manufacturing orders, supporting revenue growth. Ongoing investments in R&D and capacity expansion aim to sustain product pipeline development. Debt...
Windlas Biotech Limited reported consolidated revenue from operations of ₹1,950.19 crore for the quarter ended December 31, 2024, marking a robust year-over-year growth of 20.2% compared to ₹1,622.13 crore in the same quarter last year. This surge is likely driven by increased market demand and successful product launches in the...